MEDIA ADVISORY – FOR IMMEDIATE RELEASE
What: Protest and March Calling on Cuomo and Christie to End the Mandatory Ebola Quarantine and Support West African Nations
When: Thursday, 5pm (EST), October 30, 2014
Where: Meet Across The Street From Bellevue Hospital Center, 462 First Avenue at 27th St., New York City
Historic NYC AIDS Activist Group Marches On Cuomo's Office To Demand He Show Support For West African Nations
Thursday, October 30, at 5PM (EST), The AIDS activist group ACT UP (AIDS Coalition to Unleash Power) will rally and march from Bellevue Hospital to the governor’s office to demand that Governors Cuomo and Christie stop promoting panic-based health policies and start supporting West African nations fighting Ebola.
Last week, New York Gov. Andrew Cuomo joined New Jersey Gov. Chris Christie to announce a new policy at JFK and Newark International Airports to order immediate mandatory 21-day quarantine of any person who acknowledges having been in proximity to people with Ebola. Such policies will do nothing to protect the American public and serve as a major deterrent to the recruitment of desperately needed healthcare workers to help stop the deadly outbreak that has killed over 4500 individuals in Sierra Leone, Liberia, and Guinea. Already, Kaci Hickox, a volunteer nurse from Doctors Without Borders, was inhumanely confined for days in New Jersey, even after testing negative for the disease.
Cuomo and Christie’s mandatory quarantine policies go against
WHAT: Demonstration Against Mandatory Quarantines and in Support of All Affected by Ebola
WHEN: Thursday, Oct 30, 5 PM
WHERE: Rally in Front of Bellevue Hospital Center, 462 First Avenue (b/w 27th & 28th Streets)
March to Office of the Governor of the State of New York
633 Third Avenue (at 41st Street), New York, NY 10017
Join ACT UP/NY and allies as we demand the immediate end to mandatory quarantines and travel bans in the US, a guarantee that all US hospitals are sanctuaries for undocumented immigrants to receive care, support for all health workers, increased US funding to fight Ebola in West Africa and an end to stigmatizing the sick. The global response to the Ebola epidemic is woefully inadequate and we must act NOW to treat the epidemic at its source in coordination with local communities on the ground, respecting the human rights and dignity of all those affected by this disease. (click HERE for press release)
ACT UP! Fight Back! Fight Ebola!
ACT UP/NY has been instrumental in the roll out of pre-exposure prophylaxis, or PrEP, in NYC and State. But until now the conversation has not included women's voices. I am writing to invite you to a PrEP Rally for Women, the first community wide discussion for and by women about PrEP to prevent HIV. Co-hosted by Mt. Sinai, GMHC and ACT UP/NY, the event will be held Tuesday, October 14th, 6 - 7:30 pm at Mt. Sinai-Roosevelt Hospital, 1000 10th Ave at 59th Street, Conference Room B. Confirmed panelists include:
- Shobha Swaminathan, MD, Rutgers/New Jersey Medical School
- Poppy, woman who was on PrEP when trying to get pregnant (via video from California)
- Jasmine, woman currently on PrEP (via phone)
- Julie Lynn, woman currently on PrEP
- Kimberleigh J. Smith, Harlem United Community AIDS Center
- Lynnette Ford, MSW, GMHC
- Moderator: Terri L. Wilder, Mt. Sinai Institute for Advanced Medicine & ACT UP/NY Women's Caucus
IN SENATE LETTER, ACTIVISTS CALL FOR LOW PRICED HEPATITIS C CURE TO END THE NATIONAL EPIDEMIC
NEW YORK CITY – AUGUST 13, 2014 – Today ACT UP New York publicly challenged the U.S. Senate Finance Committee to negotiate with Gilead to reduce Sovaldi’s $1000 per pill price by 90% or more, a reduction that would save billions of dollars in U.S. health care spending, and could save hundreds of thousands more American lives, setting the groundwork for national and global eradication of hepatitis C.
Even before Gilead reported making $5.8 billion in sales on Sovaldi in just the first six months of 2014, activists, health policy experts and government officials had sharpened their criticism of the pharmaceutical company, which had previously had a relatively good reputation in the HIV community. The process by which Gilead arrived at a price for its hepatitis C drug is controversial, particularly because Gilead acquired the drug through the $11 billion purchase of the company Pharmasset, which had priced the drug significantly lower.